Concurrent Immunotherapy With Postoperative Radiotherapy in Intermediate/High Risk HNSCC Patients Unfit for Cisplatin: The IMPORT Study (IMPORT)
To investigate weather concurrent JS001 with postoperative radiotherapy would have survival benefit in intermediate/high Risk HNSCC Patients who cannot take cisplatin
Head and Neck Squamous Cell Carcinoma
RADIATION: postoperative radiotherapy|DRUG: JS001
Disease free survival, from date of enrollment until date of first documented disease progression or death from any cause, assessed up to 2 years
Overall survival, from date of enrollment until death from any cause, assessed up to 2 years|Number of participants with treatment-related acute toxicity as assessed weekly by CTCAE v4.0 during the course of treatment, Acute toxicity profiles, graded according to the NCI CTCAE version 4.0, up to 3 months after completion of radiotherapy|Number of participants with treatment-related late toxicity as assessed by CTCAE v4.0, Late toxicity profiles, graded according to the NCI CTCAE version 4.0, from 3 months after completion of radiotherapy up to 2 years
To investigate weather concurrent JS001 with postoperative radiotherapy would have survival benefit in intermediate/high Risk HNSCC Patients who cannot take cisplatin